Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -20.44% is 80% above its 5-year average of -102.66%, near the high end of its 5-year range (-150.26%–-20.44%).
54.83% above its 12-month average of -45.26%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -7.41%.
RETURN ON ASSETS (ROA)
-20.44%
RETURN ON ASSETS (ROA) AVG TTM
-45.26%
RETURN ON ASSETS (ROA) AVG 3Y
-91.41%
RETURN ON ASSETS (ROA) AVG 5Y
-102.66%
RETURN ON ASSETS (ROA) AVG 10Y
-93.08%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+54.83%
CURRENT VS 3Y AVG
+77.64%
CURRENT VS 5Y AVG
+80.09%
CURRENT VS 10Y AVG
+78.04%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-26.90%
median of 504 covered companies
CURRENT VS SECTOR MEDIAN
+24.01%
vs the sector median at left
Avalo Therapeutics, Inc.
Market Cap
$767.46M
Return on Assets (ROA)
-20.44%
TTM Avg
-45.26%
3Y Avg
-91.41%
5Y Avg
-102.66%
Market Cap
$774.32M
Return on Assets (ROA)
-36.55%
TTM Avg
-44.22%
3Y Avg
-44.22%
5Y Avg
-44.22%
Market Cap
$775.72M
Return on Assets (ROA)
-32.91%
TTM Avg
-25.26%
3Y Avg
-23.04%
5Y Avg
-20.66%
Market Cap
$776.24M
Return on Assets (ROA)
-13.47%
TTM Avg
-22.22%
3Y Avg
-41.40%
5Y Avg
-40.82%
Market Cap
$780.95M
Return on Assets (ROA)
-5.26%
TTM Avg
0.19%
3Y Avg
-3.34%
5Y Avg
-3.22%
Market Cap
$749.55M
Return on Assets (ROA)
-42.53%
TTM Avg
-41.06%
3Y Avg
-49.54%
5Y Avg
-47.47%
Market Cap
$786.48M
Return on Assets (ROA)
-18.03%
TTM Avg
-7.81%
3Y Avg
-4.40%
5Y Avg
-1.35%
Market Cap
$734.10M
Return on Assets (ROA)
-38.01%
TTM Avg
-251.96%
3Y Avg
-211.47%
5Y Avg
-174.45%
Market Cap
$812.20M
Return on Assets (ROA)
10.76%
TTM Avg
17.66%
3Y Avg
20.82%
5Y Avg
23.86%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | $767.46M | -20.44% | -45.26% | -91.41% | -102.66% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $774.32M | -36.55% | -44.22% | -44.22% | -44.22% |
| Design Therapeutics, Inc. (DSGN)vs › | $775.72M | -32.91% | -25.26% | -23.04% | -20.66% |
| Geron Corporation (GERN)vs › | $776.24M | -13.47% | -22.22% | -41.40% | -40.82% |
| AdaptHealth Corp. (AHCO)vs › | $780.95M | -5.26% | 0.19% | -3.34% | -3.22% |
| Candel Therapeutics, Inc. (CADL)vs › | $749.55M | -42.53% | -41.06% | -49.54% | -47.47% |
| Cytek Biosciences, Inc. (CTKB)vs › | $786.48M | -18.03% | -7.81% | -4.40% | -1.35% |
| Anteris Technologies Global Corp. (AVR)vs › | $734.10M | -38.01% | -251.96% | -211.47% | -174.45% |
| InMode Ltd. (INMD)vs › | $812.20M | 10.76% | 17.66% | 20.82% | 23.86% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $719.64M | -59.88% | -116.93% | -132.27% | -105.87% |
ROA
-20.4%
ROE
-22.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -67.20% |
| 2024-12-31 | -23.31% |
| 2023-12-31 | -150.26% |
| 2022-12-31 | -124.85% |
| 2021-12-31 | -105.19% |
| 2020-12-31 | -145.13% |
| 2019-12-31 | -44.51% |
| 2018-12-31 | -57.01% |
| 2017-12-31 | 27.52% |
| 2016-12-31 | -285.51% |
| 2015-12-31 | -48.43% |
| 2014-12-31 | -130.35% |
| 2013-12-31 | -257.01% |
| 2012-12-31 | -104.69% |
